Aktuelle und zukünftige Therapien der gastroösophagealen Refluxerkrankung

1. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983;98:86–95.

2. Beaumont H, Smout A, Aanen M, et al. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Aliment Pharmacol Ther 2009;30:937–46.

3. Boeckxstaens GE, Rydholm H, Lei A, et al. Effect of lesogaberan, a novel GABA-receptor agonist, on transient lower esophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 2010;31:1208–17.

4. Boeckxstaens GE. Emerging drugs for gastroesophageal reflux disease. Expert Opin Emerg Drugs 2009;14:481–91.

5. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682–6.

6. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005;3:543–52.

7. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798–810.

8. Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:208–14.

9. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710–7.

10. DeVault KR, Castell DO. ACG treatment guideline: updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999;94:1434–42.

11. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007;26:1333–44.

12. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377–90.

13. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625–32.

14. Fock KM, Ang TL. Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis. Curr Opin Investig Drugs 2008;9:1108–15.

15. Gaspar A, Ribeiro S, Nabais S, Rocha S, et al. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome. Rev Port Cardiol 2010;29:1511–20.

16. Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010;105:1266–75.

17. Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541–5.

18. Gunasekaran T, Gupta S, Gremse D, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol Nutr 2002;35(Suppl 4):S327–35.

19. Hungin AP, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 2009;30:331–42.

20. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392–1413, 1413.e1-5. Epub 2008 Sep 16.

21. Keller J, van der Voort I, Pehl C, et al. Durchführung und Interpretation der Ösophagusmanometrie: Empfehlungen der Deutschen Gesellschaften für Neurogastroenterologie und Motilität (DGNM), für Verdauungs- und Stoffwechselerkrankungen (DGVS) und für Allgemein- und Viszeralchirurgie (DGAV). Z Gastroenterol 2009;47:830–45.

22. Klotz U. Proton pump inhibitors – their pharmacological impact on the clinical management of acid-related disorders. Arzneimittelforschung 2009;59:271–82.

23. Koretz RL, Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol 2004;2:957–67.

24. Koury SI, Stone CK, La Charite DD. Omeprazole and the development of acute hepatitis. Eur J Emerg Med 1998;5:467–9.

25. Kuipers EJ. Proton pump inhibitors and Helicobacter pylori gastritis: friends or foes? Basic Clin Pharmacol Toxicol 2006;99:187–94.

26. Lacy BE, Paquette L, Robertson DJ, et al. The clinical utility of esophageal manometry. J Clin Gastroenterol 2009;43:809–15.

27. Lux G, Van Els J, The GS, et al. Ambulatory oesophageal pressure, pH and ECG recording in patients with normal and pathological coronary angiography and intermittent chest pain. Neurogastroenterol Motil 1995;7:23–30.

28. Malfertheiner P, Gerards C. Helicobacter pylori infection and gastro-oesophageal reflux disease: coincidence or association? Baillieres Best Pract Res Clin Gastroenterol 2000;14:731–41.

29. Meining A, Classen M. Gastroösophageale Refluxkrankheit. Internist 1998;39:1215–22.

30. Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:2692–7.

31. Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci 2008;53:2621–6.

32. Nguyen HN, Silny J, Matern S. Multiple intraluminal electrical impedancometry for recording of upper gastrointestinal motility: current results and further implications. Am J Gastroenterol 1999;94:306–17.

33. Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009;154:514–20.

34. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335–9.

35. Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005;18:370–3.

36. Raiha IJ, Impivaara O, Seppala M, Sourander LB. Prevalence and characteristics of symptomatic gastroesophageal reflux disease in the elderly. J Am Geriatr Soc 1992;40:1209–11.

37. Richter JE, Sabesin S, Kogut D, et al. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic GERD. Am J Gastroenterol 1996;91:1766–72.

38. Ruigomez A, Rodriguez LA, Wallander MA, et al. Endoscopic findings in a cohort of newly diagnosed gastroesophageal reflux disease patients registered in a UK primary care database. Dis Esophagus 2008;21:251–6.

39. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23(Suppl 2):2–8.

40. Schindlbeck N. Diagnosis and clinical course in gastroesophageal reflux. Fortschr Med 1996;114:31–4.

41. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024–31.

42. Sifrim D, Dupont L, Blondeau K, et al. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut 2005;54:449–54.

43. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011;123:474–82.

44. Smout AJ. Review article: The measurement of non-acid gastro-oesophageal reflux. Aliment Pharmacol Ther 2007;26(Suppl 2):7–12.

45. Storr M, Allescher HD. Barrett-Ösophagus, gastroösophagealer Reflux und Helicobacter pylori als Risikofaktoren für das Adenokarzinom der Speiseröhre. Verdauungskrankh 2000;18:57–62.

46. Storr M, Allescher HD. Motilitätsmodifizierende Pharmaka. Internist 2000;12:1318–30.

47. Storr M, Allescher HD. Reflux disease as a motility disorder: treatment alternatives to acid suppression. Gastroenterology 2010;139:2207–9.

48. Storr M, Meining A, Allescher HD. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig Dis 2000;18:93–102.

49. Storr M, Meining A, Allescher HD. Pharmacoeconomic issues of the therapy of gastroesophageal reflux disease. Exp Opin Pharmacother 2001;2:1099–108.

50. Storr MA. What is nonacid reflux disease? Can J Gastroenterol 2011;25:35–8.

51. Talley NJ. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005;129:1753–5.

52. Van Soest EM, van Rossum LG, Dieleman JP, van Oijen MG, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008;103:966–73.

53. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001;120:1599–606.

54. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003;17:243–51.

55. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689–96.

56. Von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007;102:1268–75.

57. Werning C (Hrsg.). Medizin für Apotheker. Ein Handbuch mit Grundwissen für die Praxis. 3. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2008.

58. Wilde MI, McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994;48:91–132.

59. Yip D, Kovac S, Jardine M, et al. Omeprazole-induced interstitial nephritis. J Clin Gastroenterol 1997;25:450–2.

Priv.-Doz. Dr. med. Martin Storr, Medizinische Klinik II der Ludwig-Maximilians-Universität München, Klinikum Großhadern, Marchioninistraße 15, 81377 München, E-Mail: grdoc@gmx.com